首页 > 最新文献

Reviews on recent clinical trials最新文献

英文 中文
Comparing the Effects of Pregabalin and Clonidine on Postoperative Pain in Tonsillectomy: A Randomized, Double-Blind, Prospective Clinical Trial. 比较普瑞巴林和氯硝柳胺对扁桃体切除术术后疼痛的影响:随机、双盲、前瞻性临床试验。
IF 1.9 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2022-09-22 DOI: 10.2174/1574887117666220922092953
Shahryar Sane, Rahman Abbasi Vash, Nazila Rahmani, Hadi Talebi, Parang Golabi, Farid Kalashipour, Poneh Heidari, Mohammad-Foad Hatami, Behzad Kazemi Haki, Shabnam Morwati

Background: Tonsillectomy is one of the most common surgical procedures. This study compared the effect of Pregabalin and Clonidine on postoperative pain in adult patients undergoing elective tonsillectomy.

Methods: This randomized, double-blind, prospective clinical trial was conducted among 92 patients aged 20 to 50. The clonidine group (C) was given 150 µg of clonidine tablet 90 minutes before surgery, and the pregabalin group (P) was given 300 mg of pregabalin tablet 90 minutes before surgery. The results were analyzed by SPSS 25, and statistical analysis consisted of chisquare, T-test, and χ2 tests, and a p-value less than 0.05 was considered significant.

Results: The mean pain score and analgesic consumption scores in the pregabalin group were lower than in the clonidine group. According to the t-test, there was a significant difference between the two groups regarding pain score and analgesic consumption (p <0.05). Hemodynamic variation in both groups had no significant differences (p >0.05).

Conclusion: The present study showed that pregabalin reduced postoperative pain and analgesic consumption more effectively than clonidine.

背景:扁桃体切除术是最常见的外科手术之一:扁桃体切除术是最常见的外科手术之一。本研究比较了普瑞巴林和氯硝柳胺对接受扁桃体切除术的成年患者术后疼痛的影响:这项随机、双盲、前瞻性临床试验在 92 名 20 至 50 岁的患者中进行。克洛尼定组(C)在手术前 90 分钟服用 150 微克克洛尼定片,普瑞巴林组(P)在手术前 90 分钟服用 300 毫克普瑞巴林片。结果采用 SPSS 25 进行分析,统计分析包括方差分析、T 检验和 χ2 检验,P 值小于 0.05 为差异有显著性:普瑞巴林组的平均疼痛评分和镇痛药消耗评分均低于氯硝柳胺组。根据 t 检验,两组在疼痛评分和镇痛药消耗量方面存在显著差异(P 0.05):本研究表明,普瑞巴林比氯尼替丁更有效地减轻了术后疼痛和镇痛药用量。
{"title":"Comparing the Effects of Pregabalin and Clonidine on Postoperative Pain in Tonsillectomy: A Randomized, Double-Blind, Prospective Clinical Trial.","authors":"Shahryar Sane, Rahman Abbasi Vash, Nazila Rahmani, Hadi Talebi, Parang Golabi, Farid Kalashipour, Poneh Heidari, Mohammad-Foad Hatami, Behzad Kazemi Haki, Shabnam Morwati","doi":"10.2174/1574887117666220922092953","DOIUrl":"10.2174/1574887117666220922092953","url":null,"abstract":"<p><strong>Background: </strong>Tonsillectomy is one of the most common surgical procedures. This study compared the effect of Pregabalin and Clonidine on postoperative pain in adult patients undergoing elective tonsillectomy.</p><p><strong>Methods: </strong>This randomized, double-blind, prospective clinical trial was conducted among 92 patients aged 20 to 50. The clonidine group (C) was given 150 µg of clonidine tablet 90 minutes before surgery, and the pregabalin group (P) was given 300 mg of pregabalin tablet 90 minutes before surgery. The results were analyzed by SPSS 25, and statistical analysis consisted of chisquare, T-test, and χ2 tests, and a p-value less than 0.05 was considered significant.</p><p><strong>Results: </strong>The mean pain score and analgesic consumption scores in the pregabalin group were lower than in the clonidine group. According to the t-test, there was a significant difference between the two groups regarding pain score and analgesic consumption (p <0.05). Hemodynamic variation in both groups had no significant differences (p >0.05).</p><p><strong>Conclusion: </strong>The present study showed that pregabalin reduced postoperative pain and analgesic consumption more effectively than clonidine.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2022-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33481369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of age and gender disparity on CD4+ cell counts to control disease progression using specific HAART in HIV-1 positive patients: A case-control study. 年龄和性别差异对 HIV-1 阳性患者使用特定 HAART 控制疾病进展的 CD4+ 细胞计数的影响:病例对照研究。
IF 1.9 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2022-08-17 DOI: 10.2174/1574887117666220817123002
Aakansha Singh, Manoj Kumar, Ashok K Singh, Neeraj Verma

Background: Highly Active Antiretroviral Therapy (HAART) is composed of several drugs in the antiretroviral class to better treat human immunodeficiency virus type 1 (HIV-1) patients. The estimation of CD4+ T cell counts and HIV-1 viral load in plasma is required to evaluate the treatment success of a specific HAART.

Methodology: The study included the effects of NRTIs (nucleoside reverse transcriptase inhibitors) and novel protease inhibitors (HAART) on normal control subjects and HIV-1 positive subjects from SGPGIMS, Lucknow, with different age groups and genders. Furthermore, the study was conducted by the estimation of HIV through ELISA, measurement of absolute CD4+ cell count, and the measurement of viral load through qRT-PCR. Furthermore, NRTIs (Retrovir and Epivir) were administered orally one tablet daily in the morning followed by newly FDA-approved protease inhibitors (fosamprenavir and darunavir) orally in the evening at the same dose. Furthermore, CD4+T cell counts and HIV-1 viral load were investigated and correlated in patients with different genders and age groups.

Result: Administration of NRTIs and novel protease inhibitors (HAART) in HIV patients had a significant effect on the CD4+ cell count in various age intervals among males and females. The mean comparison of viral load distribution based on gender in CD4 +ve patients in the case group exhibited a viral load higher in females compared to males, indicating a statistically significant difference between males and females (p<0.05). A notable association between virological and immunological parameters was observed with a reciprocal relationship between viral load and CD4 cell count in CD4 +ve patients, demonstrating multiple correlation coefficients with an R-value of 0.853.

Conclusion: The administration of specific HAART (NRTIs and novel protease inhibitors) in HIV patients had a notable improvement in the CD4+ cell count and viral load with significant age and gender disparity.

背景:高活性抗逆转录病毒疗法(HAART高活性抗逆转录病毒疗法(HAART)由多种抗逆转录病毒类药物组成,旨在更好地治疗1型人类免疫缺陷病毒(HIV-1)患者。评估特定 HAART 的治疗成功与否,需要估算血浆中 CD4+ T 细胞计数和 HIV-1 病毒载量:研究包括 NRTIs(核苷酸逆转录酶抑制剂)和新型蛋白酶抑制剂(HAART)对正常对照组和勒克瑙 SGPGIMS 的 HIV-1 阳性受试者不同年龄组和性别的影响。此外,该研究还通过酶联免疫吸附试验(ELISA)估算艾滋病毒感染率,测量 CD4+ 细胞绝对计数,以及通过 qRT-PCR 测量病毒载量。此外,每天早上口服一片 NRTIs(Retrovir 和 Epivir),晚上以相同剂量口服美国 FDA 批准的新蛋白酶抑制剂(福沙那韦和达鲁那韦)。此外,还对不同性别和年龄组患者的 CD4+T 细胞计数和 HIV-1 病毒载量进行了调查和相关性分析:结果:HIV 患者服用 NRTIs 和新型蛋白酶抑制剂(HAART)对不同年龄段男性和女性的 CD4+ 细胞计数有显著影响。病例组 CD4+ve 患者基于性别的病毒载量分布平均值比较显示,女性的病毒载量高于男性,这表明男性和女性之间存在显著的统计学差异(p):对艾滋病患者使用特定的 HAART(NRTIs 和新型蛋白酶抑制剂)可明显改善 CD4+ 细胞计数和病毒载量,但存在明显的年龄和性别差异。
{"title":"Impact of age and gender disparity on CD4+ cell counts to control disease progression using specific HAART in HIV-1 positive patients: A case-control study.","authors":"Aakansha Singh, Manoj Kumar, Ashok K Singh, Neeraj Verma","doi":"10.2174/1574887117666220817123002","DOIUrl":"10.2174/1574887117666220817123002","url":null,"abstract":"<p><strong>Background: </strong>Highly Active Antiretroviral Therapy (HAART) is composed of several drugs in the antiretroviral class to better treat human immunodeficiency virus type 1 (HIV-1) patients. The estimation of CD4+ T cell counts and HIV-1 viral load in plasma is required to evaluate the treatment success of a specific HAART.</p><p><strong>Methodology: </strong>The study included the effects of NRTIs (nucleoside reverse transcriptase inhibitors) and novel protease inhibitors (HAART) on normal control subjects and HIV-1 positive subjects from SGPGIMS, Lucknow, with different age groups and genders. Furthermore, the study was conducted by the estimation of HIV through ELISA, measurement of absolute CD4+ cell count, and the measurement of viral load through qRT-PCR. Furthermore, NRTIs (Retrovir and Epivir) were administered orally one tablet daily in the morning followed by newly FDA-approved protease inhibitors (fosamprenavir and darunavir) orally in the evening at the same dose. Furthermore, CD4+T cell counts and HIV-1 viral load were investigated and correlated in patients with different genders and age groups.</p><p><strong>Result: </strong>Administration of NRTIs and novel protease inhibitors (HAART) in HIV patients had a significant effect on the CD4+ cell count in various age intervals among males and females. The mean comparison of viral load distribution based on gender in CD4 +ve patients in the case group exhibited a viral load higher in females compared to males, indicating a statistically significant difference between males and females (p<0.05). A notable association between virological and immunological parameters was observed with a reciprocal relationship between viral load and CD4 cell count in CD4 +ve patients, demonstrating multiple correlation coefficients with an R-value of 0.853.</p><p><strong>Conclusion: </strong>The administration of specific HAART (NRTIs and novel protease inhibitors) in HIV patients had a notable improvement in the CD4+ cell count and viral load with significant age and gender disparity.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2022-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40622249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Measuring Mood and Anxiety Disorders by Patient Reported Outcomes in Inflammatory Bowel Disease: A Literature Review Update. 通过患者报告结果衡量炎症性肠病患者的情绪和焦虑障碍:最新文献综述。
IF 1.9 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2022-06-28 DOI: 10.2174/1574887117666220628151256
Rocco Spagnuolo, Antonio Basile, Alessandro Corea, Francesco Salvatore Iaquinta, Nataša Milić, Patrizia Doldo, Francesco Luzza, Ludovico Abenavoli

Background Anxiety and depression are the most common psychological disorders found in Inflammatory Bowel Disease (IBD) patients. Accurate measuring of these disorders should be proposed for a prompt management. Patient-reported outcome measurements (PROMs) allow patients to self-report their psychological symptoms. Objective To highlight the presence of PROMs measuring anxiety and depression in IBD setting evaluating the most used psychometric tools. Methods We reviewed the literature from 2010 up to September 2021. Articles on adult IBD patients assessing depression and anxiety by PROMs in English language were included. Results Thirty-six studies, including 11 psychometric tools were found. Hospital Anxiety and Depression Scale (21 studies), Beck Depression Inventory II (5 studies), Spielberg State-Trait Anxiety Inventory (3 studies), Patient-Reported Outcomes Measurement Information System (3 studies), Symptom Checklist-90 (2 studies), Euro Quality of Life (2 studies) mostly used psychometric tools for anxiety and depression in IBD settings. Conclusion Our review analyzed psychometric tools used for PROMs evaluating anxiety and depression in IBD setting. No chronological differences have emerged, all have been used in the last ten years, highlighting a lack of specificity. The strong association between IBD and mood disorders suggests that clinicians should consider the evaluation of depression and anxiety as integral parts of IBD clinical care. It is essential to identify tools enabling these items to be detected better. A global view of IBD patients, accounting not only for physical but also for psychical symptoms with an early and feasible assessment of unrecognized psychiatric disorders, can have a strong impact on their management strategy.

背景焦虑和抑郁是炎症性肠病(IBD)患者最常见的心理障碍。应建议对这些心理障碍进行准确测量,以便及时进行治疗。患者报告结果测量法(PROMs)允许患者自我报告其心理症状。目的 通过评估最常用的心理测量工具,强调在 IBD 环境中测量焦虑和抑郁的 PROMs 的存在。方法 我们回顾了 2010 年至 2021 年 9 月的文献。纳入了关于成年 IBD 患者使用 PROM 评估抑郁和焦虑的英文文章。结果 找到了 36 项研究,包括 11 种心理测量工具。医院焦虑抑郁量表(21 项研究)、贝克抑郁量表 II(5 项研究)、斯皮尔伯格状态-特质焦虑量表(3 项研究)、患者报告结果测量信息系统(3 项研究)、症状检查表-90(2 项研究)、欧洲生活质量(2 项研究)是 IBD 环境中最常用的焦虑和抑郁心理测量工具。结论 我们的综述分析了用于评估 IBD 环境中焦虑和抑郁的 PROM 的心理测量工具。所有这些工具都是在过去十年中使用的,并没有出现时间上的差异,这说明这些工具缺乏特异性。IBD 与情绪障碍之间的密切联系表明,临床医生应将抑郁和焦虑的评估视为 IBD 临床护理的组成部分。有必要确定能够更好地检测这些项目的工具。对 IBD 患者进行全面观察,不仅要考虑躯体症状,还要考虑精神症状,并对未被发现的精神障碍进行早期可行的评估,这将对患者的管理策略产生重大影响。
{"title":"Measuring Mood and Anxiety Disorders by Patient Reported Outcomes in Inflammatory Bowel Disease: A Literature Review Update.","authors":"Rocco Spagnuolo, Antonio Basile, Alessandro Corea, Francesco Salvatore Iaquinta, Nataša Milić, Patrizia Doldo, Francesco Luzza, Ludovico Abenavoli","doi":"10.2174/1574887117666220628151256","DOIUrl":"10.2174/1574887117666220628151256","url":null,"abstract":"<p><p>Background Anxiety and depression are the most common psychological disorders found in Inflammatory Bowel Disease (IBD) patients. Accurate measuring of these disorders should be proposed for a prompt management. Patient-reported outcome measurements (PROMs) allow patients to self-report their psychological symptoms. Objective To highlight the presence of PROMs measuring anxiety and depression in IBD setting evaluating the most used psychometric tools. Methods We reviewed the literature from 2010 up to September 2021. Articles on adult IBD patients assessing depression and anxiety by PROMs in English language were included. Results Thirty-six studies, including 11 psychometric tools were found. Hospital Anxiety and Depression Scale (21 studies), Beck Depression Inventory II (5 studies), Spielberg State-Trait Anxiety Inventory (3 studies), Patient-Reported Outcomes Measurement Information System (3 studies), Symptom Checklist-90 (2 studies), Euro Quality of Life (2 studies) mostly used psychometric tools for anxiety and depression in IBD settings. Conclusion Our review analyzed psychometric tools used for PROMs evaluating anxiety and depression in IBD setting. No chronological differences have emerged, all have been used in the last ten years, highlighting a lack of specificity. The strong association between IBD and mood disorders suggests that clinicians should consider the evaluation of depression and anxiety as integral parts of IBD clinical care. It is essential to identify tools enabling these items to be detected better. A global view of IBD patients, accounting not only for physical but also for psychical symptoms with an early and feasible assessment of unrecognized psychiatric disorders, can have a strong impact on their management strategy.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2022-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40411214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PSSD and biologic therapy: Real-life data in 417 patients with moderate to severe psoriasis. PSSD 和生物疗法:417 名中度至重度银屑病患者的真实生活数据。
IF 1.9 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2022-06-23 DOI: 10.2174/1574887117666220623161751
Ilaria Proietti, Nicoletta Bernardini, Nevena Skroza, Alessandra Mambrin, Ersilia Tolino, Anna Marchesiello, Federica Marraffa, Giovanni Rossi, Salvatore Volpe, Concetta Potenza

Background: Psoriasis is a chronic relapsing immune-mediated disease leading to a strong impact on patient's quality of life. The treatment of psoriasis has undergone a revolution with the advent of biologic therapies. Currently, Psoriasis Area and Severity Index [PASI] and Dermatology Life Quality Index [DLQI] scores are in use to assess the overall severity of pathology. A new self- administered questionnaire, the Psoriasis Symptoms and Signs Diary (PSSD), assesses severity of six psoriasis symptoms (itch, skin tightness, burning, stinging, and pain,) and five signs (dryness, cracking, scaling, shedding/flaking, redness, and bleeding).

Objective: To evaluate and compare the efficacy of biologic therapies through PSSD in patients with moderate to severe psoriasis Methods: The PSSD questionnaire was administered to all the patients at the beginning and after 6 months of biologic therapy (anti-TNFalpha, anti- IL17, anti-IL23, anti-IL12/23 and phhosphodiesterase-4 Inhibitors).

Results: The study population included 417 adult patients with moderate to severe psoriasis in treatment with biologic drugs. All the drugs contributed to a significant improvement of mean total PSSD at t 24; anti-IL17 and anti-IL23 led to a significantly greater reduction at t 24 mean PSSD when compared to other therapies.

Conclusion: The PSSD, is a new validated instrument useful for capturing psoriasis patient's quality of life and evaluating treatments efficacy. In our study this score has been useful to put in evidence significant differences between biologic drugs.

背景:银屑病是一种慢性复发性免疫介导疾病,严重影响患者的生活质量。随着生物疗法的出现,银屑病的治疗经历了一场革命。目前,银屑病面积和严重程度指数(PASI)和皮肤病生活质量指数(DLQI)被用来评估病变的整体严重程度。一种新的自我管理问卷--银屑病症状和体征日记(PSSD)可评估六种银屑病症状(瘙痒、皮肤紧绷、灼热、刺痛和疼痛)和五种体征(干燥、皲裂、脱屑、脱落/剥落、发红和出血)的严重程度:通过 PSSD 评估和比较生物疗法对中重度银屑病患者的疗效:所有患者在接受生物疗法(抗肿瘤坏死因子α、抗IL17、抗IL23、抗IL12/23和磷酸二酯酶-4抑制剂)之初和6个月后均接受了PSSD问卷调查:研究对象包括417名接受生物制剂治疗的中重度银屑病成年患者。与其他疗法相比,抗IL17和抗IL23能显著降低24小时的平均总PSSD:PSSD是一种新的有效工具,可用于了解银屑病患者的生活质量和评估治疗效果。在我们的研究中,该评分有助于证明生物药物之间的显著差异。
{"title":"PSSD and biologic therapy: Real-life data in 417 patients with moderate to severe psoriasis.","authors":"Ilaria Proietti, Nicoletta Bernardini, Nevena Skroza, Alessandra Mambrin, Ersilia Tolino, Anna Marchesiello, Federica Marraffa, Giovanni Rossi, Salvatore Volpe, Concetta Potenza","doi":"10.2174/1574887117666220623161751","DOIUrl":"10.2174/1574887117666220623161751","url":null,"abstract":"<p><strong>Background: </strong>Psoriasis is a chronic relapsing immune-mediated disease leading to a strong impact on patient's quality of life. The treatment of psoriasis has undergone a revolution with the advent of biologic therapies. Currently, Psoriasis Area and Severity Index [PASI] and Dermatology Life Quality Index [DLQI] scores are in use to assess the overall severity of pathology. A new self- administered questionnaire, the Psoriasis Symptoms and Signs Diary (PSSD), assesses severity of six psoriasis symptoms (itch, skin tightness, burning, stinging, and pain,) and five signs (dryness, cracking, scaling, shedding/flaking, redness, and bleeding).</p><p><strong>Objective: </strong>To evaluate and compare the efficacy of biologic therapies through PSSD in patients with moderate to severe psoriasis Methods: The PSSD questionnaire was administered to all the patients at the beginning and after 6 months of biologic therapy (anti-TNFalpha, anti- IL17, anti-IL23, anti-IL12/23 and phhosphodiesterase-4 Inhibitors).</p><p><strong>Results: </strong>The study population included 417 adult patients with moderate to severe psoriasis in treatment with biologic drugs. All the drugs contributed to a significant improvement of mean total PSSD at t 24; anti-IL17 and anti-IL23 led to a significantly greater reduction at t 24 mean PSSD when compared to other therapies.</p><p><strong>Conclusion: </strong>The PSSD, is a new validated instrument useful for capturing psoriasis patient's quality of life and evaluating treatments efficacy. In our study this score has been useful to put in evidence significant differences between biologic drugs.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2022-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40394225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnosis and Acute Treatment of Ischemic Stroke. 缺血性中风的诊断和急性治疗。
IF 1.9 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2022-06-17 DOI: 10.2174/1574887117666220617103114
Ernesto Cristiano Lauritano, Federica Nicoletta Sepe, Maria Carmela Mascolo, Riccardo Boverio, Luigi Ruiz

Stroke is defined as an acute cerebrovascular accident characterized by an interruption of vascular supply lasting more than 24 hours. Therapeutic goal, reassumed at the well-known "time is brain", is strictly focused on achieving timely restoration of cerebral blood flow at risk of infarction to reduce neurological complications. Consequently, time to treatment is the most important determinant of the efficacy of reperfusion. Current guidelines strongly recommend the use of intravenous thrombolysis with tissue plasminogen activator and endovascular thrombectomy to reach that goal. These therapies allow to obtain 1.9 million neurons saved per each minute of onset-to-reperfusion time and 4.2 days of extra healthy life and are crucial in the reduction of mortality and morbidity of ischemic stroke. Multidisciplinary collaboration involving a coordinated prehospital management and stroke team composed of physicians with expertise in emergency medicine, neurologists, radiologists, nurses, technicians, and laboratory personnel are essential for rapid triage and should guide clinical decisions to deliver the appropriate reperfusion therapy for each patient.

脑卒中是指血管供应中断超过 24 小时的急性脑血管意外。众所周知,"时间就是大脑",治疗目标严格集中在及时恢复有梗死风险的脑血流,以减少神经系统并发症。因此,治疗时间是决定再灌注疗效的最重要因素。目前的指南强烈建议使用组织凝血酶原激活剂静脉溶栓和血管内血栓切除术来实现这一目标。这些疗法可以在发病到再灌注的每一分钟内挽救 190 万个神经元,延长 4.2 天的健康寿命,对降低缺血性中风的死亡率和发病率至关重要。由急诊科医生、神经科医生、放射科医生、护士、技术人员和实验室人员组成的院前协调管理和中风团队的多学科合作对于快速分诊至关重要,并应指导临床决策,为每位患者提供适当的再灌注治疗。
{"title":"Diagnosis and Acute Treatment of Ischemic Stroke.","authors":"Ernesto Cristiano Lauritano, Federica Nicoletta Sepe, Maria Carmela Mascolo, Riccardo Boverio, Luigi Ruiz","doi":"10.2174/1574887117666220617103114","DOIUrl":"10.2174/1574887117666220617103114","url":null,"abstract":"<p><p>Stroke is defined as an acute cerebrovascular accident characterized by an interruption of vascular supply lasting more than 24 hours. Therapeutic goal, reassumed at the well-known \"time is brain\", is strictly focused on achieving timely restoration of cerebral blood flow at risk of infarction to reduce neurological complications. Consequently, time to treatment is the most important determinant of the efficacy of reperfusion. Current guidelines strongly recommend the use of intravenous thrombolysis with tissue plasminogen activator and endovascular thrombectomy to reach that goal. These therapies allow to obtain 1.9 million neurons saved per each minute of onset-to-reperfusion time and 4.2 days of extra healthy life and are crucial in the reduction of mortality and morbidity of ischemic stroke. Multidisciplinary collaboration involving a coordinated prehospital management and stroke team composed of physicians with expertise in emergency medicine, neurologists, radiologists, nurses, technicians, and laboratory personnel are essential for rapid triage and should guide clinical decisions to deliver the appropriate reperfusion therapy for each patient.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2022-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39999403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hepatic Encephalopathy by Manganese Deposition: A Case Report and a Review of Literature. 锰沉积引起的肝性脑病:病例报告和文献综述。
IF 1.9 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2022-06-17 DOI: 10.2174/1574887117666220617104539
Ludovico Abenavoli, Giulia Fabiano, Anna Caterina Procopio, Isabella Aquila, Rinaldo Pellicano, Stefania Barone, Maurizio Morelli, Francesco Luzza

Background: Hepatic encephalopathy is defined as a spectrum of neuropsychiatric disorders in patients with liver dysfunction, usually cirrhosis, after exclusion of brain disease. This study reports the role of manganese in brain alterations and therefore in clinical manifestations of hepatic encephalopathy.

Case presentation: Male patient, 67 years old, suffering from alcoholic liver cirrhosis and two previous episodes of hepatic encephalopathy, developed drowsiness, asterixis, amnesia, disorientation in time and space, and psychomotor retardation. Brain MRI without contrast showed: initial signs of cerebral atrophy, a hyperintense signal of globi pallidi and bilateral substantia nigra. The hyperintense signal of globi pallidi is the result of manganese deposition in the brain.

Conclusion: The case report presented supports the data reported in the literature indicating that the increase in plasma manganese levels in subjects with liver dysfunction is correlated with the onset of extrapyramidal symptoms.

背景:肝性脑病是指肝功能异常(通常为肝硬化)患者在排除脑部疾病后出现的一系列神经精神障碍。本研究报告了锰在脑部改变中的作用,以及锰在肝性脑病临床表现中的作用:男性患者,67 岁,患有酒精性肝硬化,曾两次发作肝性脑病,出现嗜睡、眼花、健忘、时空错乱和精神运动迟滞。无造影剂的脑部磁共振成像显示:最初的脑萎缩迹象、苍白球和双侧黑质的高强度信号。苍白球高信号是锰在大脑中沉积的结果:本病例报告支持文献报道的数据,即肝功能异常患者血浆锰水平的升高与锥体外系症状的出现相关。
{"title":"Hepatic Encephalopathy by Manganese Deposition: A Case Report and a Review of Literature.","authors":"Ludovico Abenavoli, Giulia Fabiano, Anna Caterina Procopio, Isabella Aquila, Rinaldo Pellicano, Stefania Barone, Maurizio Morelli, Francesco Luzza","doi":"10.2174/1574887117666220617104539","DOIUrl":"10.2174/1574887117666220617104539","url":null,"abstract":"<p><strong>Background: </strong>Hepatic encephalopathy is defined as a spectrum of neuropsychiatric disorders in patients with liver dysfunction, usually cirrhosis, after exclusion of brain disease. This study reports the role of manganese in brain alterations and therefore in clinical manifestations of hepatic encephalopathy.</p><p><strong>Case presentation: </strong>Male patient, 67 years old, suffering from alcoholic liver cirrhosis and two previous episodes of hepatic encephalopathy, developed drowsiness, asterixis, amnesia, disorientation in time and space, and psychomotor retardation. Brain MRI without contrast showed: initial signs of cerebral atrophy, a hyperintense signal of globi pallidi and bilateral substantia nigra. The hyperintense signal of globi pallidi is the result of manganese deposition in the brain.</p><p><strong>Conclusion: </strong>The case report presented supports the data reported in the literature indicating that the increase in plasma manganese levels in subjects with liver dysfunction is correlated with the onset of extrapyramidal symptoms.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2022-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39999404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Value of Rox Index to Predict Intubation and Intensive Care Unit Outcome in Patients with Respiratory Failure. Rox指数预测呼吸衰竭患者插管和重症监护室结果的价值。
IF 1.9 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2022-06-06 DOI: 10.2174/1574887117666220606114549
Ayshan Mammadova, Esra Eriş, Zeynep Sena Solmaz, Ayşe Taşçı Kara, Aydın Atasoy, Gül Gürsel

Background: Recent literature suggests that the respiratory rate oxygenation (ROX) index may be a useful parameter in predicting intubation indication in hypoxemic patients.

Objective: In this study, we evaluated the accuracy of the ROX index in predicting intubation, length of stay in the ICU, and mortality in ICU patients with hypoxemic respiratory failure with and without hypercapnia.

Methods: Single-centre retrospective cohort study of 290 patients, with a preliminary diagnosis of respiratory failure, who were treated with low flow oxygen systems. Demographics, medical history, clinical, laboratory, treatment, and prognostic data were obtained from the electronic records of the hospital. The ROX index was calculated at the time of ICU admission.

Results: Thirty-seven percent of non-hypercapnic and 69% of hypercapnic patients were intubated (p:0.005). In hypercapnic patients, ROX: 6.9 had highest sensitivity (81%) and specificity (65%) values for intubation (p:0.005). In non-hypercapnic patients, ROX: 6.2 had the highest sensitivity (81%) and specificity (40%) values. While 11% of hypercapnic patients and 30% of non-hypercapnic patients were died (p:0.05), 22% of hypercapnic patients and 33% of non-hypercapnic patients stayed in the ICU longer than 14 days (p:0.044). The highest sensitivity and specificity values were found for mortality in hypercapnic patients; for ROX value of 5.94 (sensitivity:86%, specificity:61%) and for ICU stay longer than 14 days; for ROX value of 7.4 (sensitivity:71%, specificity:68%).

Conclusion: Results of our study suggest that ROX index calculated during ICU admission can be helpful in predicting intubation indication and length of ICU stay in patients with respiratory failure and hypercapnia may influence the cutoff values.

背景最近的文献表明,呼吸速率氧合(ROX)指数可能是预测低氧血症患者插管指征的有用参数。目的在本研究中,我们评估了ROX指数在预测伴有和不伴有高碳酸血症的低氧性呼吸衰竭ICU患者的插管、ICU住院时间和死亡率方面的准确性。方法对290名初步诊断为呼吸衰竭并接受低流量氧气系统治疗的患者进行单中心回顾性队列研究。从医院的电子记录中获得人口统计学、病史、临床、实验室、治疗和预后数据。ROX指数在入住ICU时进行计算。结果约有7%的非高碳酸血症患者和69%的高碳酸血症病人插管(p:0.005)。在高碳酸血症的患者中,ROX:6.9对插管的敏感性(81%)和特异性(65%)最高(p:0.005)。在非高碳酸症的病人中,ROX:6.2的敏感性(81%)和特异度(40%)最高。11%的高碳酸血症和30%的非高碳酸血症患者死亡(p:0.05),22%的高碳酸症患者和33%的非高二氧化碳血症患者在ICU停留时间超过14天(p:0.044);ROX值为5.94(敏感性:86%,特异性:61%),ICU住院时间超过14天;ROX值为7.4(敏感性:71%,特异性:68%)。结论我们的研究结果表明,在ICU入院期间计算的ROX指数有助于预测呼吸衰竭和高碳酸血症患者的插管指征和ICU住院时间可能会影响临界值。
{"title":"Value of Rox Index to Predict Intubation and Intensive Care Unit Outcome in Patients with Respiratory Failure.","authors":"Ayshan Mammadova, Esra Eriş, Zeynep Sena Solmaz, Ayşe Taşçı Kara, Aydın Atasoy, Gül Gürsel","doi":"10.2174/1574887117666220606114549","DOIUrl":"10.2174/1574887117666220606114549","url":null,"abstract":"<p><strong>Background: </strong>Recent literature suggests that the respiratory rate oxygenation (ROX) index may be a useful parameter in predicting intubation indication in hypoxemic patients.</p><p><strong>Objective: </strong>In this study, we evaluated the accuracy of the ROX index in predicting intubation, length of stay in the ICU, and mortality in ICU patients with hypoxemic respiratory failure with and without hypercapnia.</p><p><strong>Methods: </strong>Single-centre retrospective cohort study of 290 patients, with a preliminary diagnosis of respiratory failure, who were treated with low flow oxygen systems. Demographics, medical history, clinical, laboratory, treatment, and prognostic data were obtained from the electronic records of the hospital. The ROX index was calculated at the time of ICU admission.</p><p><strong>Results: </strong>Thirty-seven percent of non-hypercapnic and 69% of hypercapnic patients were intubated (p:0.005). In hypercapnic patients, ROX: 6.9 had highest sensitivity (81%) and specificity (65%) values for intubation (p:0.005). In non-hypercapnic patients, ROX: 6.2 had the highest sensitivity (81%) and specificity (40%) values. While 11% of hypercapnic patients and 30% of non-hypercapnic patients were died (p:0.05), 22% of hypercapnic patients and 33% of non-hypercapnic patients stayed in the ICU longer than 14 days (p:0.044). The highest sensitivity and specificity values were found for mortality in hypercapnic patients; for ROX value of 5.94 (sensitivity:86%, specificity:61%) and for ICU stay longer than 14 days; for ROX value of 7.4 (sensitivity:71%, specificity:68%).</p><p><strong>Conclusion: </strong>Results of our study suggest that ROX index calculated during ICU admission can be helpful in predicting intubation indication and length of ICU stay in patients with respiratory failure and hypercapnia may influence the cutoff values.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2022-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47693884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Satisfaction in Social Roles and Physical Function in Immune-mediated Inflammatory Diseases: A Cross-Sectional Study. 在免疫介导的炎症疾病中社会角色满意度和身体功能:一项横断面研究。
IF 1.9 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2022-05-31 DOI: 10.2174/1574887117666220531162104
Rocco Spagnuolo, Francesco Salvatore Iaquinta, Daniele Mauro, Ilenia Pantano, Stefano Dastoli, Saverio Naty, Cristina Cosco, Rosellina Margherita Mancina, Daniela Iacono, Emanuela Gaggiano, Annarita Ruggiero, Steven Paul Nisticò, Francesco Ciccia, Rosa Daniela Grembiale, Doldo Patrizia

Background: Although mood disorders have been well characterized in Immune-mediated inflammatory diseases, physical function and satisfaction in social roles have not yet been defined as independent domains.

Objective: The study aims to assess satisfaction in social roles and physical function alterations in an Immune-mediated inflammatory diseases population and identify associated characteristics.

Methods: Physical function and social roles satisfaction were evaluated through the Patient-Reported Outcomes Measurement System. Besides comparisons between groups, univariate and multivariable logistic regression were performed to identify independent predictors.

Results: Two hundred sixty-five Immune-mediated Inflammatory Diseases patients and 206 controls were recruited. Compared with controls, Inflammatory Bowel Diseases patients had impaired physical function (p<0.001), while Inflammatory Arthritis patients reported impairment in both domains (p<0.001, each). In the univariate logistic regression, gender, high school educational level, physical activity and occupation were positively associated with physical function and social role satisfaction (p<0.001; p=0.001; p<0.001; p=0.001 and p<0.001; p=0.012; p=0.008; p=0.004, respectively). Active disease and steroids were inversely associated with physical function and social roles satisfaction (p=0.033; p=0.022 and p=0.002; p=0.038, respectively). Further associations were found between age and physical function (p=0.002); biological treatment and ESR with social roles satisfaction (p<0.001; p=0.043; respectively). In the multivariable regression, gender remained associated with physical function (p<0.001) and social roles satisfaction (p=0.003). Negatively associated factors were biological treatment for satisfaction in social roles (p<0.001) and steroids for physical function (p=0.021) and social roles satisfaction (p=0.018).

Conclusion: Immune-mediated Inflammatory diseases determine alterations in physical function and social life satisfaction. Gender and treatment are independent associated factors. Patient-Reported Outcomes should be considered in clinical management to define patients' real needs.

虽然情绪障碍在免疫介导的炎症性疾病中有很好的特征,但身体功能和社会角色满意度尚未被定义为独立的领域。目的:本研究旨在评估免疫介导炎性疾病人群的社会角色满意度和身体功能改变,并确定相关特征。方法采用患者报告结果测量系统对患者的身体功能和社会角色满意度进行评估。除了组间比较外,还进行了单变量和多变量逻辑回归以确定独立预测因子。结果共纳入免疫介导性炎症性疾病患者265例,对照组206例。与对照组相比,炎症性肠病患者的身体功能受损(p<0.001),而炎症性关节炎患者的身体功能受损(p<0.001)。在单变量logistic回归中,性别、高中文化程度、体力活动和职业与身体功能和社会角色满意度呈正相关(p<0.001;p = 0.001;p < 0.001;P =0.001和P <0.001;p = 0.012;p = 0.008;分别为p = 0.004)。活动性疾病和类固醇与身体功能和社会角色满意度呈负相关(p=0.033;P =0.022和P =0.002;分别为p = 0.038)。年龄和身体机能之间存在进一步的关联(p=0.002);生物治疗和ESR与社会角色满意度(p<0.001);p = 0.043;分别)。在多变量回归中,性别仍然与身体功能(p<0.001)和社会角色满意度(p=0.003)相关。负相关因素为社会角色满意度的生物治疗(p<0.001)和身体功能的类固醇(p=0.021)和社会角色满意度(p=0.018)。结论免疫介导的炎症性疾病决定身体功能和社会生活满意度的改变。性别和治疗是独立的相关因素。临床管理应考虑患者报告的结果,以确定患者的真正需求。
{"title":"Satisfaction in Social Roles and Physical Function in Immune-mediated Inflammatory Diseases: A Cross-Sectional Study.","authors":"Rocco Spagnuolo, Francesco Salvatore Iaquinta, Daniele Mauro, Ilenia Pantano, Stefano Dastoli, Saverio Naty, Cristina Cosco, Rosellina Margherita Mancina, Daniela Iacono, Emanuela Gaggiano, Annarita Ruggiero, Steven Paul Nisticò, Francesco Ciccia, Rosa Daniela Grembiale, Doldo Patrizia","doi":"10.2174/1574887117666220531162104","DOIUrl":"10.2174/1574887117666220531162104","url":null,"abstract":"<p><strong>Background: </strong>Although mood disorders have been well characterized in Immune-mediated inflammatory diseases, physical function and satisfaction in social roles have not yet been defined as independent domains.</p><p><strong>Objective: </strong>The study aims to assess satisfaction in social roles and physical function alterations in an Immune-mediated inflammatory diseases population and identify associated characteristics.</p><p><strong>Methods: </strong>Physical function and social roles satisfaction were evaluated through the Patient-Reported Outcomes Measurement System. Besides comparisons between groups, univariate and multivariable logistic regression were performed to identify independent predictors.</p><p><strong>Results: </strong>Two hundred sixty-five Immune-mediated Inflammatory Diseases patients and 206 controls were recruited. Compared with controls, Inflammatory Bowel Diseases patients had impaired physical function (p<0.001), while Inflammatory Arthritis patients reported impairment in both domains (p<0.001, each). In the univariate logistic regression, gender, high school educational level, physical activity and occupation were positively associated with physical function and social role satisfaction (p<0.001; p=0.001; p<0.001; p=0.001 and p<0.001; p=0.012; p=0.008; p=0.004, respectively). Active disease and steroids were inversely associated with physical function and social roles satisfaction (p=0.033; p=0.022 and p=0.002; p=0.038, respectively). Further associations were found between age and physical function (p=0.002); biological treatment and ESR with social roles satisfaction (p<0.001; p=0.043; respectively). In the multivariable regression, gender remained associated with physical function (p<0.001) and social roles satisfaction (p=0.003). Negatively associated factors were biological treatment for satisfaction in social roles (p<0.001) and steroids for physical function (p=0.021) and social roles satisfaction (p=0.018).</p><p><strong>Conclusion: </strong>Immune-mediated Inflammatory diseases determine alterations in physical function and social life satisfaction. Gender and treatment are independent associated factors. Patient-Reported Outcomes should be considered in clinical management to define patients' real needs.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2022-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47806506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Should SARS CoV-2 infection be considered an independent risk factor for Pneumocystis jirovecii pneumonia? Emerging data after two years of pandemic from a single center experience. 严重急性呼吸系统综合征冠状病毒2型感染是否应被视为吉氏肺孢子虫肺炎的独立危险因素?来自单一中心的两年疫情后的新兴数据。
IF 1.9 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2022-05-11 DOI: 10.2174/1574887117666220511123826
Antonio Riccardo Buonomo, Giulio Viceconte, Biagio Pinchera, Riccardo Scotto, Emanuela Zappulo, Maria Foggia, Ivan Gentile
{"title":"Should SARS CoV-2 infection be considered an independent risk factor for Pneumocystis jirovecii pneumonia? Emerging data after two years of pandemic from a single center experience.","authors":"Antonio Riccardo Buonomo, Giulio Viceconte, Biagio Pinchera, Riccardo Scotto, Emanuela Zappulo, Maria Foggia, Ivan Gentile","doi":"10.2174/1574887117666220511123826","DOIUrl":"10.2174/1574887117666220511123826","url":null,"abstract":"","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2022-05-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44873174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patient-Reported Outcomes Measures in Perianal Fistulizing Crohn's Disease. 肛门周围瘘管性克罗恩病患者报告的结果测量。
IF 1.9 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2022-04-25 DOI: 10.2174/1574887117666220425125424
Natália Sousa Freitas Queiroz, Karoline Soares Garcia, Eron Fabio Miranda, Paulo Gustavo Kotze

Perianal fistulizing Crohn's disease (PFCD) is a disabling complication of Crohn's disease (CD) that can significantly impact on patients' quality of life (QoL) and often requires multidisciplinary care. Clinical trials assessing the efficacy of medical and surgical interventions for fistulas usually evaluate outcomes such as closure of fistula tracts or radiologic healing. However, these traditional outcome assessments fail in capturing the impact of the disease from patients' perspectives. In this context, regulatory authorities have increasingly encouraged the inclusion of validated patient-reported outcomes (PRO) that assess disease activity and reveal how a patient functions and feels. This recent trend towards patient-centered care aims to ensure that improvements in efficacy outcomes are accompanied by meaningful benefits to patients. The aim of this review is to discuss currently available PRO measures (PROMS) for the assessment of PFCD to provide to physicians appropriate tools aiming to optimize patient care and disseminate the use of these instruments in clinical practice.

肛周瘘管性克罗恩病(PFCD)是克罗恩病(CD)的致残性并发症,可显著影响患者的生活质量(QoL),通常需要多学科治疗。临床试验评估药物和手术干预对瘘管的疗效通常评估结果,如瘘管束闭合或放射治疗愈合。然而,这些传统的结果评估未能从患者的角度捕捉疾病的影响。在这种情况下,监管机构越来越鼓励纳入经过验证的患者报告结果(PRO),以评估疾病活动并揭示患者的功能和感觉。这种以患者为中心的护理的最新趋势旨在确保疗效结果的改善伴随着对患者的有意义的益处。本综述的目的是讨论目前可用的评估PFCD的PRO措施(PROMS),为医生提供适当的工具,旨在优化患者护理,并在临床实践中推广这些工具的使用。
{"title":"Patient-Reported Outcomes Measures in Perianal Fistulizing Crohn's Disease.","authors":"Natália Sousa Freitas Queiroz, Karoline Soares Garcia, Eron Fabio Miranda, Paulo Gustavo Kotze","doi":"10.2174/1574887117666220425125424","DOIUrl":"10.2174/1574887117666220425125424","url":null,"abstract":"<p><p>Perianal fistulizing Crohn's disease (PFCD) is a disabling complication of Crohn's disease (CD) that can significantly impact on patients' quality of life (QoL) and often requires multidisciplinary care. Clinical trials assessing the efficacy of medical and surgical interventions for fistulas usually evaluate outcomes such as closure of fistula tracts or radiologic healing. However, these traditional outcome assessments fail in capturing the impact of the disease from patients' perspectives. In this context, regulatory authorities have increasingly encouraged the inclusion of validated patient-reported outcomes (PRO) that assess disease activity and reveal how a patient functions and feels. This recent trend towards patient-centered care aims to ensure that improvements in efficacy outcomes are accompanied by meaningful benefits to patients. The aim of this review is to discuss currently available PRO measures (PROMS) for the assessment of PFCD to provide to physicians appropriate tools aiming to optimize patient care and disseminate the use of these instruments in clinical practice.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2022-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44834756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Reviews on recent clinical trials
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1